Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature

Article Hematology

Daratumumab as a novel treatment option in refractory ITP

Ilze Vernava et al.

Summary: We report the clinical courses of two adult patients with primary immune thrombocytopenia (ITP) who had multiple relapses and exhausted standard therapies. They were treated with the off-label use of the myeloma-licensed anti-CD38 monoclonal antibody daratumumab. The first patient showed a rapid and lasting response, with platelet counts above the normal range. The second patient achieved clinical stabilization. Daratumumab effectively targets long-lived plasma cells as the source of ITP-mediating autoantibodies, suggesting its potential in broader clinical evaluation.

BLOOD CELLS MOLECULES AND DISEASES (2023)

Add to Collection

Article Immunology

Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Maria A. A. Pereda et al.

Summary: In this article, three patients are described who were treated with daratumumab for conditions other than post-transplant autoimmune cytopenias, demonstrating additional potential uses of this medication.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Hematology

How I treat cold agglutinin disease

Sigbjorn Berentsen

Summary: Significant progress has been made in the treatment of CAD in recent decades, with recommendations mainly based on nonrandomized trials and personal experience due to the lack of comparative trials. Individualized treatment options tailored to patients' symptoms and disease characteristics are crucial to avoid ineffective therapies.

BLOOD (2021)

Add to Collection

Article Immunology

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease

Anna Zaninoni et al.

Summary: Daratumumab, a monoclonal antibody targeting CD38, has shown efficacy in multiple myeloma and is now being investigated for its potential in treating autoimmune conditions like cold agglutinin disease. The drug not only depletes plasma cells but also demonstrates immunomodulatory effects by influencing the levels of various cytokines. Research also suggests its potential in refractory autoimmune hemolytic anemia, Evans syndrome, and other autoimmune diseases.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Hematology